Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003

被引：0
|
作者：
Goldschmidt, Hartmut
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Alexandra Hosp, Athens, Greece
[3] Univ Tubingen Hosp, Dept Med, Tubingen, Germany
[4] Hop Hotel Dieu, Univ Hosp, Nantes, France
[5] Mayo Clin, Rochester, MN USA
[6] Vancouver Gen Hosp, Vancouver, BC, Canada
[7] Katholieke Univ Leuven Hosp, Dept Hematol, Louvain, Belgium
[8] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France
[9] Ctr Hosp Cote Basque, Bayonne, France
[10] HGTiP, Inst Catala Oncol, Barcelona, Spain
[11] Celgene Corp, Summit, NJ USA
[12] Hosp Univ Salamanca, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8528
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey S. Y.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth C.
    BLOOD, 2022, 140
  • [32] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
    Richardson, Paul
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
  • [33] LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
    Kupas, K.
    Kaspar, I.
    Baecke, V.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 514 - 515
  • [34] Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)
    Qian, Xiaozhong
    Newhall, Kathryn
    Tometsko, Mark
    Bjorklund, Chad
    Ma, Jianglin
    Bahlis, Nizar J.
    Siegel, David
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin W.
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanthi
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Mouro, Jorge
    Agarwal, Amit
    Zafar, Faiza
    Thakurta, Anjan
    BLOOD, 2017, 130
  • [35] The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in refractory or relapsed and refractory multiple myeloma
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Cavo, Michele
    Corradini, Paolo
    Delforge, Michel
    Morgan, Gareth J.
    Hansson, Markus
    Palumbo, Antonlo
    Oclo, Enrique M.
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Leupin, Nicolas
    Nikolova, Zariana G.
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
    Vij, Ravi
    Richardson, Paul Gerard Guy
    Jagannath, Sundar
    Siegel, David Samuel DiCapua
    Baz, Rachid C.
    Srinivasan, Shankar
    Larkins, Gail
    Zaki, Mohamed H.
    Hussein, Mohamad A.
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [38] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
    Jagannath, Sundar
    Hofmeister, Craig C.
    Baz, Rachid C.
    Siegel, David Samuel DiCapua
    Vij, Ravi
    Chen, Christine
    Lonial, Sagar
    Anderson, Kenneth Carl
    Chen, Min
    Zaki, Mohamed H.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
    Moreau, Philippe
    Weisel, Katja C.
    Song, Kevin W.
    Gibson, Craig J.
    Saunders, Owain
    Sternas, Lars Axel
    Hong, Kevin
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2839 - 2847
  • [40] Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis
    Weisel, Katja
    Dimopoulos, Meletios Athanasios
    Van de Donk, Niels
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Kueenburg, Elisabeth
    Collins, Shona
    Lersch, Frederik
    Rosettani, Barbara
    Bacon, Pamela
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E145 - E145
12345